RT Journal Article
SR Electronic
T1 Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2379
OP 2386
DO 10.21873/anticanres.14207
VO 40
IS 4
A1 WATANABE, DAICHI
A1 FUJII, HIRONORI
A1 MATSUHASHI, NOBUHISA
A1 IIHARA, HIROTOSHI
A1 YAMADA, YUNAMI
A1 ISHIHARA, TAKUMA
A1 TAKAHASHI, TAKAO
A1 YOSHIDA, KAZUHIRO
A1 SUZUKI, AKIO
YR 2020
UL http://ar.iiarjournals.org/content/40/4/2379.abstract
AB Background/Aim: The effect of renal dysfunction on the toxicity and efficacy of oxaliplatin remains unclear. We investigated the association between creatinine clearance (Ccr), a marker of renal function, and the toxicity and efficacy of oxaliplatin in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Patients with mCRC who received oxaliplatin-based chemotherapy as first-line treatment were included in this study. Primary outcome was peripheral neuropathy (Grade ≥2), while secondary outcomes included neutropenia (Grade ≥3), thrombocytopenia (Grade ≥2) and overall survival (OS). Results: A total of 145 patients with mCRC were eligible. Incidence rates of peripheral neuropathy (Grade ≥2), neutropenia (Grade ≥3) and thrombocytopenia (Grade ≥2) were 30.3%, 37.2% and 16.6%, respectively, and median OS was 29.1 months. Cox proportional hazards analysis indicated that there was no significant relationship between Ccr and any adverse event, or between Ccr and OS. Conclusion: Dose reduction of oxaliplatin based on Ccr is not recommended in patients with mCRC.